Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 20
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Dig Liver Dis ; 39(6): 589-96, 2007 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-17459794

RESUMEN

Although adverse effects of nonsteroidal anti-inflammatory drugs occur in only a small proportion of users, the widespread use of these drugs has resulted in a substantial overall number of affected persons who experience serious gastrointestinal complications. Dyspeptic symptoms are estimated to occur in 10-60% of nonsteroidal anti-inflammatory drug users and lead to discontinuation of treatment in 5-15% of rheumatoid arthritis patients taking nonsteroidal anti-inflammatory drugs. It is now well established that the point prevalence of peptic ulcer disease in patients receiving conventional nonsteroidal anti-inflammatory drug therapy ranges between 10 and 30%, representing a 10- to 30-fold increase over that found in the general population. One out of 175 users of conventional nonsteroidal anti-inflammatory drugs in the USA will be hospitalized each year for nonsteroidal anti-inflammatory drug-induced gastrointestinal damage. The mortality of hospitalized patients remains about 5-10%, with an expected annual death rate of 0.08%. The selective COX-2 inhibitors consistently show comparable efficacy to that of conventional nonsteroidal anti-inflammatory drugs in patients with rheumatoid arthritis and osteoarthritis, but have a reduced propensity to cause gastrointestinal toxicity. In many cases, the gastric effects of therapeutically active doses of COX-2 inhibitors are indistinguishable from placebo. The safety benefits of COX-2 inhibitors given alone appear similar to those of combined therapy with conventional nonsteroidal anti-inflammatory drugs and gastroprotective agents. These findings warrant the consideration of COX-2 inhibitors as first-line therapy in patients requiring long-term pain control.


Asunto(s)
Antiinflamatorios no Esteroideos/uso terapéutico , Inhibidores de la Ciclooxigenasa 2/uso terapéutico , Enfermedades Gastrointestinales/tratamiento farmacológico , Antiinflamatorios no Esteroideos/efectos adversos , Inhibidores de la Ciclooxigenasa 2/efectos adversos , Humanos , Médicos , Ensayos Clínicos Controlados Aleatorios como Asunto , Factores de Riesgo
2.
Dig Liver Dis ; 35(5): 325-31, 2003 May.
Artículo en Inglés | MEDLINE | ID: mdl-12846404

RESUMEN

BACKGROUND: Data concerning the usefulness and type of drugs employed to treat patients with primary sclerosing cholangitis are controversial. Ursodeoxycholic acid has been shown to be a useful agent, however the drug dosage and its effect on the clinical course are still under debate. AIM: To evaluate the efficacy of low-dose ursodeoxycholic acid in the treatment of primary sclerosing cholangitis. METHODS: We retrospectively analysed data from 86 patients with primary sclerosing cholangitis from eight centres in Italy between 1987 and 1997: 69 were treated with ursodeoxycholic acid (8-13 mg/kg/day), while 17 received symptomatic treatment and served as controls. The effect of therapy was evaluated by standard liver function tests and symptom analysis. RESULTS: Ursodeoxycholic acid treatment was associated with significant improvement in serum alkaline phosphatase (735+/-833 vs. 519+/-448 U/l, p<0.001), gamma-glutamyl transpeptidase (401+/-352 vs. 234+/-235 U/l, p<0.001), aspartate aminotransferase (87+/-70 vs. 56+/-42 U/l, p=0.001), alanine aminotransferase (146+/-139 vs. 76+/-73 U/l, p<0.001), and total bilirubin (1.88+/-2.44 vs. 1.76+/-4.12 U/l, p=0.01); there was also amelioration of fatigue (p=0.007), jaundice (p=0.002), and body weight loss (p=0.002). CONCLUSIONS: Ursodeoxycholic acid, at a dose of 8-13 mg/kg/day was beneficial for the general condition and liver biochemistry of patients with primary sclerosing cholangitis; high-dose ursodeoxycholic acid treatment requires further evaluation.


Asunto(s)
Colagogos y Coleréticos/administración & dosificación , Colangitis Esclerosante/tratamiento farmacológico , Ácido Ursodesoxicólico/administración & dosificación , Adulto , Anciano , Femenino , Humanos , Italia , Pruebas de Función Hepática , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Resultado del Tratamiento
3.
Ann Ital Chir ; 62(2): 185-9; discussion 189-90, 1991.
Artículo en Italiano | MEDLINE | ID: mdl-1755599

RESUMEN

Primitive actinomycotic abscess of the liver is extremely rare: in the world literature are reported twenty cases. The authors report a case of a 73-year-old patient admitted at our hospital in poor general conditions, with twelve kilograms weight loss in the last year, recurrent fever and tenderness in right hypochondrium. CT scan, ultrasonography and angiography showed the presence of a seven-centimeters hypovascularized mass in the fourth segment of the liver. The patient was submitted to surgical segmentectomy of the fourth segment. The histologic examination and the histochemical colorations made on the specimen have given the diagnosis of hepatic actinomycotic abscess. No clinical evidence of other intra-abdominal or extra-abdominal localizations were found. From 1928 to date only twenty similar cases have been reported in the world literature. The mean time between the beginning of the symptoms and the diagnosis was 11.1 months (range: 2-54 months): this to confirm the diagnostic difficulties of the disease. The hepatic lesions are described as single in eight cases and multiple in thirteen. Thirteen patients have been treated only with medical therapy: nine recovered and four died for disease spread. Of the six patients with resectable lesion treated surgically, five recovered and one died for pulmonary recurrence.


Asunto(s)
Actinomicosis/diagnóstico , Hepatopatías/diagnóstico , Actinomicosis/patología , Actinomicosis/cirugía , Anciano , Diagnóstico Diferencial , Hepatectomía , Humanos , Hígado/patología , Hepatopatías/patología , Hepatopatías/cirugía , Masculino
4.
J Int Med Res ; 18(5): 341-50, 1990.
Artículo en Inglés | MEDLINE | ID: mdl-2257957

RESUMEN

The efficacy of a combination of ranitidine and pirenzepine in the short-term treatment of duodenal ulcer was evaluated in a double-blind trial. In a multicentre study, 352 patients with active duodenal ulcers were randomly allocated to be treated with 300 mg/day ranitidine plus placebo (group I), 300 mg/day ranitidine plus 50 mg/day pirenzepine (group II), or 300 mg/day ranitidine plus 100 mg/day pirenzepine (group III) for 4 weeks. The respective healing rates assessed using endoscopic examination after 2 and 4 weeks' treatment were 40% and 70% in group 1, 44% and 82% in group II, and 37% and 77% in group III. The differences between the treatment groups were not significant, although 300 mg/day ranitidine plus 50 mg/day pirenzepine tended to be superior to the other treatments. Analgesic activity was the same in the three groups with 33%, 34% and 33% reductions, respectively, in the numbers of patients experiencing pain after 2 weeks. Side-effects (mainly dry mouth and blurred vision) were significantly more frequent in group III patients.


Asunto(s)
Úlcera Duodenal/tratamiento farmacológico , Pirenzepina/uso terapéutico , Ranitidina/uso terapéutico , Adulto , Método Doble Ciego , Quimioterapia Combinada , Duodenoscopía , Femenino , Humanos , Masculino , Pirenzepina/administración & dosificación , Ranitidina/administración & dosificación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...